Company record
A clear public starting point.
This page gathers the company’s published description, taxonomy, status, and official link in one place. It does not make claims about private activity or deal terms.
Startup in Sahin’s portfolio

Genetic engineering for de-extinction and species restoration
| Round | Raised | Date |
|---|---|---|
| Series C | $200M | 2025 |
| Series C | $120M | 2025 |
Total raised: $435MCompany value: Valued at $10.3B
Colossal Biosciences is a Dallas-based genetics company that calls itself the first de-extinction company. It is best known for its effort to bring back traits of the woolly mammoth, and it also works on species such as the thylacine and the dodo.
Source: Dallas Innovates
Entrepreneur Ben Lamm and Harvard geneticist George Church founded Colossal in 2021. Lamm leads the company as CEO.
Source: Dallas Innovates
Colossal was valued at $10.32 billion as of September 2025, according to Colossal Biosciences (press release via Business Wire).
Source: Colossal Biosciences (press release via Business Wire)
As an angel investor in 231 startups across 14 categories, I look for companies with exceptional founders, large addressable markets, and clear competitive advantages. Colossal stood out in the Biotech space.
Company record
This page gathers the company’s published description, taxonomy, status, and official link in one place. It does not make claims about private activity or deal terms.